Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study
Mylène Duivon(Inserm), Florence Joly(Centre François Baclesse), Marie Lange(Inserm), Jean-Baptiste Méric(Institut National du Cancer), Cécile Charles(Université de Bordeaux), Régine Kiasuwa-Mbengi(Sciensano (Belgium)), Giulia Binarelli(University Hospital of Lausanne), Isabelle Hardy‐Léger(Hôpital Cochin), Johan Lefel(Centre Henri Becquerel)
Cited by 22
Related Papers
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
|Journal of Clinical Oncology|2018|330
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)
|European Journal of Cancer|2005|241
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
|Nature Medicine|2021|115
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
|British Journal of Cancer|2016|48
Cancer-related cognitive impairment: current perspectives on the management of cognitive changes following cancer treatment
|Expert Review of Neurotherapeutics|2023|31